journal cover

Panobinostat for the Treatment of Multiple Myeloma

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research

Sep 13, 2015

Jacob P LaubachPaul G Richardson

Download from

Publisher
PubMed

Abstract

Panobinostat is a potent oral deacetylase inhibitor that alters gene expression through epigenetic mechanisms and inhibits protein degradation. It was recently approved by the FDA and EMA for use in combination with bortezomib and dexamethasone in patients with multiple myeloma who have...read more

Mentioned in this Paper

MEA Protocol
United States Food and Drug Administration
Treatment Protocols
Antineoplastic Agents
Protein Degradation, Regulatory
Panobinostat
Hydroxamic Acids
Inhibitors
Protein Degradation, Metabolic
Bortezomib
6
119
Paper Details
References
  • References
  • Citations36
  • finger pointing at paper

    References currently unavailable

    We're still populating references for this paper, please check back later.
  • References
  • Citations36
1234

Feeds With Similar Papers

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Cancer Genomics

Cancer genomics employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research here.

Multiple Myeloma

Multiple Myeloma is a cancer of the plasma cells, which normally is involved in antibody production. Discover the latest research on Multiple Myeloma here.

Epigenetics (Keystone)

Epigenetics is the study of heritable changes in gene expression that do not involve alteration of the DNA sequence. Here is the latest research.

Epigenetics

Epigenetics is the study of heritable changes in gene expression that do not involve alteration of the DNA sequence. Here is the latest research.

Related Papers

Blood

Carfilzomib(opens in new tab)

BloodFebruary 9, 2013
K Martin Kortuem, A Keith Stewart
© 2020 Meta ULC. All rights reserved

Panobinostat for the Treatment of Multiple Myeloma

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research

Sep 13, 2015

Jacob P LaubachPaul G Richardson

PMID: 26362997

DOI: 10.1158/1078-0432.ccr-15-0530

Abstract

Panobinostat is a potent oral deacetylase inhibitor that alters gene expression through epigenetic mechanisms and inhibits protein degradation. It was recently approved by the FDA and EMA for use in combination with bortezomib and dexamethasone in patients with multiple myeloma who have...read more

Mentioned in this Paper

MEA Protocol
United States Food and Drug Administration
Treatment Protocols
Antineoplastic Agents
Protein Degradation, Regulatory
Panobinostat
Hydroxamic Acids
Inhibitors
Protein Degradation, Metabolic
Bortezomib
6
119

Feeds With Similar Papers

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Cancer Genomics

Cancer genomics employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research here.

Related Papers

Blood

Carfilzomib(opens in new tab)

BloodFebruary 9, 2013
K Martin Kortuem, A Keith Stewart
Paper Details
References
  • References
  • Citations36
  • finger pointing at paper

    References currently unavailable

    We're still populating references for this paper, please check back later.
  • References
  • Citations36
1234

Download from

Publisher
PubMed
/papers/panobinostat-for-the-treatment-of-multiple/26362997